2019, FDA Approval, Pharmacokinetics and Protein Expression

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2019

FDA Approval

Pharmacokinetics

Protein Expression

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

Alta Sciences

APRIL 17, 2024

Ketamine is a dissociative anesthetic approved in 2019 by the U.S. Food and Drug Administration (FDA) as a nasal spray called esketamine, for treatment-resistant depression. And since proteins are often linked to disease, there's huge potential to treat a broad range of diseases with this technology. Asia, and Europe.

Drug Development

Drug Development Treatment FDA Approval Therapies

2021 AAN highlight impact and breadth of expanding neuroscience portfolio

The Pharma Data

APRIL 8, 2021

Food and Drug Administration (FDA) approved EVRYSDI for the treatment of SMA in adults and children 2 months of age and older. EVRYSDI was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively.

Clinical Trials

Clinical Trials Trials Disease Nurses

Drug Discovery Digest

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

2021 AAN highlight impact and breadth of expanding neuroscience portfolio

Stay Connected